 |
| Tickets are available in advance for a $25.00 donation |
|
|
The RSG1 Foundation is currently privately funding new therapies for the treatment of brain tumors and cancers. Innovative therapies are expected to produce additional treatment options that will increase the survival rate of pediatric and adult brain tumor patients. The RSG1 Foundation is currently funding and providing kits for oncology patients who require necessary items to manage the therapeutic KD protocol for brain tumors and other cancers.
The mission of the RSG1 Foundation is to fund research, awareness and education of Glucose Transporters and Glucose Metabolism which affect the treatment of brain tumors, cancer, Alzheimer's,Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS), epilepsy, ALS, heart disease and diabetes.
RSG1 is interested in funding the advancement of novel treatment and therapy approaches such as the Ketogenic Diet and Ketone Ester. Research and education of these progressive alternatives have been shown to help children and adults suffering from brain tumors, cancer, epilepsy and neurodegenerative disease. RSG1 is committed and invested in these type of initiatives in order to save lives!
Advancing these types of research projects will also tell scientists more about the functionality of Glut1 and how it affects other neurological diseases.
The RSG1 Foundation is currently investigating therapeutic alternatives for Glut1 DS patients. Specific interests are funding ketone ester supplement/therapy for a Glut1 DS rodent pilot-study.
|
Background Statement
The RSG1 Foundation was founded in January 2010 by Samra R. Savioz, to raise funds that will enable the advancement of therapies and treatments for diseases affected by Glucose Transporters and Glucose Metabolism. These diseases include brain tumors, cancer, Glut1 DS, diabetes, ALS, epilepsy, Alzheimer's and neurodegenerative disease, as well as to raise money to support patient needs, awareness and education.
Ms.Savioz founded RSG1 after being told by researchers that little could be done to help her daughter Remi ,who was diagnosed with a rare brain disease due to a lack of funding.
|
Community Vision
To improve and enhance the lives of patients suffering from acute, chronic and terminal metabolic and neurodegenerative disease.
|
Foundation Partners & Affiliates
The RSG1 Foundation is proud to announce its partnership and affiliation with the Boilermakers Local 154, the United Way of Allegheny County, Pittsburgh Gives, The Pittsburgh Foundation, NORD (National Organization of Rare Disorders), Rare Disease Day 2011 and the Dick's Sporting Goods Pittsburgh Marathon, Barrow Neurological Institute, and Childrens Hospital of Pittsburgh at UPMC.
|
An International Cohort of Research Brings Promise- RSG1 GT Conference 2012
The RSG1 Glucose Transporter Conference was held on July 6 & 7, 2012 in Orlando, Florida. This conference represents the first time researchers would gather at a medical conference to discuss the role that glucose transporters and the role they can play in managing metabolic diseases such as cancer, Alzheimer's, epilepsy, neurodegenerative disease, diabetes and Glut1 DS.
Conference Findings & Features:
- Insights into Glut1 transport in the brain that will open doors to understanding the structural basis of these transporters and provide a basis to expand the clinical spectrum.
- Existing therapies for cancers, Alzheimer’s, epilepsy, Glut1 DS, diabetes and ALS.
- Alternative therapies types, which can have broader applications, like restoring cognitive function to Alzheimer’s patients, treating diseases such as Glut1 DS, cancers, or preventing seizures.
- Applying knowledge about glucose metabolism in the brain for obesity and diabetes treatment.
“Coming out of the conference we see an increased collaboration among these leading researchers to catalyze more research and insights into the role glucose transporters can play,” stated Dr. Michael Mueckler, Ph.D., Professor of Cell Biology and Physiology.
“At this conference and with our new found relationship with the RSG1 Foundation, we were able to share our laboratory’s research which is focused on exploiting the anti-seizure and neuroprotective effects of therapeutic ketosis with the development and testing of ketone esters. Ketone esters may offer great hope for patients with drug-resistant seizure disorders, including GLUT-1 deficiency syndrome,” stated Dr. Dominic D’Agostino, Ph.D., Professor of Molecular Pharmacology and Physiology.
|
|
 |
| Team RSG1 |
|
|
|
|
 |
| Book/Code No: 10231835 |
|
|
|
|
